No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Gene and cell therapy company Oxford Biomedica said on Wednesday that it has expanded its strategic partnership with Bristol Myers Squibb, inking a new commercial supply agreement for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes.
Under the new agreement, Oxford Biomedica was expected to commence commercial manufacturing at its facilities in Oxford and Durham, North Carolina in 2026, subject to regulatory approval.
Oxford Biomedica expects the supply agreement to generate "meaningful multi-year revenue" and support existing medium-term financial guidance. It also noted that the expanded partnership builds on the pair's existing relationship, which was originally announced in March 2020.
As of 0815 GMT, Oxford Biomedica shares were up 1.83% at 833p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.